Please login to the form below
Monsanto
This page shows the latest Monsanto news and features for those working in and with pharma, biotech and healthcare.
Bayer axes 1,250 pharma jobs, with R&D taking the brunt
The shake-up – which follows its $66bn takeover of agricultural products company Monsanto – will also result in the sale of its animal health division to narrow its focus to pharma, consumer ... and agility.” He also insisted that the moves have
Latest news
-
Pharma sales help Bayer escape the worst from a bumpy 2017
group Monsanto - which it now expects to complete before June - won’t derail its other business units.
-
Joerg Moeller to head Bayer R&D after operational shake-up
Moeller is taking over the R&D helm at a pivotal point for Bayer, which has been in the throes of a mega-merger with Monsanto - finalised today - while also working
-
EMA clears Bayer's Stivarga for liver cancer
PAH) therapy Adempas (riociguat) - that Bayer needs to drive its pharma unit as it digests Monsanto - bought for $66bn last September.
-
Bayer: Post-truth politics severely handicaps innovation
US of Bayer’s $66bn acquisition of agri-business firm Monsanto.
-
Xarelto and Eylea continue to dominate Bayer's pharma sales
Monsanto acquisition 'won't curtail pharma deals'. Overall, group sales rise 1.5% to 46.8bn in 2016, in a year that saw Bayer agree in September a $66bn deal to ... and that the company's long-term funding plans would not be impacted by the Monsanto deal.
More from news
Approximately 3 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
Innovation in merger control and the impact on the pharmaceutical sector
This was its position in the recent Dow/ DuPont and Bayer/Monsanto mergers, where the Commission found that each transaction would have ‘significantly reduced competition in a number of markets’ and
-
Taking a lean and careful approach
He has also served as a group leader at Monsanto Co, a senior staff fellow at the National Institutes of Health and as an assistant professor at the University of Maryland.
-
Deal Watch May 2016
In the same vein, focusing its interests, Bayer put in a $62bn opening bid [$122 per share] to purchase Monsanto, which bid has been rejected as insufficient.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Alexion Pharmaceuticals adds to its board
Reinsdorf, who has a background in corporate governance and expertise in managing corporate and legal affairs, has served in various positions for companies including Tyco International and Monsanto.
-
Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences
Shailubhai has also previously served at Callisto Pharmaceuticals, Monsanto Company and as a senior staff fellow at the National Institutes of Health (NIH).
-
H&T Asia promotes Monika James
Monsanto, MSD and Danone.
-
JDRF names new CEO
The choice is a change of direction for Rapp, who was most recently mergers and acquisitions lead for the chemical firm Monsanto Company and has served as CEO of the
-
Peacock steps down as Amgen CFO
His prior experience includes roles at Tanox, Biogen and Monsanto Life Sciences.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
